Can a Two-Drug combo help young people with new type 1 diabetes keep making insulin?

NCT ID NCT06455319

Recruiting now Disease control Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a low dose of anti-thymocyte globulin (ATG), followed by verapamil, can help preserve the body's ability to produce insulin in adolescents and young adults recently diagnosed with type 1 diabetes. The study will enroll 60 people aged 6 to 35 who have had diabetes for less than 100 days. Researchers will use a blood test to predict who will respond best to ATG, and then add verapamil to reduce stress on insulin-making cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-thymocyte globulin (ATG) and verapamil
What this could lead to: If successful, this could lead to a treatment that helps people with newly diagnosed type 1 diabetes keep making their own insulin longer, reducing the need for injected insulin.
What could go wrong: This is an early phase 2 trial with only 60 participants, so results may not apply to everyone. The treatment may not work for all, and side effects from ATG or verapamil are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Locations

Barbara Davis Center for Diabetes
RECRUITING

Aurora, Colorado, 80045, United States
University of Florida
RECRUITING

Gainesville, Florida, 32610, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.